While a significant increase in percentage of CD8β+ T cells was found at the tumor site (mean values: 39.7% in contrast to 13.3% for the PBMC samples) (Figure 2C), the proportion of CD4+ T cells expressing the CD8α+ activation molecule was significantly reduced within tumor isolates (Figure 2D). The gene discussed is CD8A; the disease is neoplasm.